Modernizing Diagnosis in Early-Stage Glaucoma - On Demand Video


Activity Description

This video compendium provides in-depth insights from members of an expert consensus panel that convened to reach a consensus on the management of early-stage glaucoma. It focuses on modernizing diagnosis in early-stage glaucoma, the roles of SLT as and sustained-release drug delivery in early-stage glaucoma, and personalized, patient-centric glaucoma management to enhance the care of patients with early-stage glaucoma.

Learning Objectives:

Upon completion of this activity, the participant should be able to: 

1. Define and assess the incidence, risk factors, and diagnostic tools for early detection of glaucoma.

2. Compare and integrate treatment options and decision-making processes for glaucoma management.

3. Evaluate and implement patient communication strategies and non-preset scans for enhanced care.


Accreditation

ACCME Accredited

The Fundingsland Group, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Credit Designation Statement

The Fundingsland Group, LLC designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Release Date: 10-31-2025

Expiration Date: 10-30-2026

Target Audience

This accredited educational activity is designed for ophthalmologists.

Grant Support Statement

This activity is supported by unrestricted educational grants from AbbVie, Alcon, and Glaukos.

Participation Method

Once you’re logged into the course, you must complete the pre-test, view the activity, successfully pass the post-test, and complete the evaluation.
Only candidates with a passing score of at least 70% earn CE credit. Candidates have the opportunity to retake the post-test until a passing score is achieved. The course credit certificate will appear in the Certificates section of your account automatically upon successful completion of the course.

Faculty                                                                                                                                                                                                                                                                                                                                                             

Lorraine Provencher

Lorraine M. Provencher, MD
  • Cataract, Anterior Segment, and Glaucoma Surgeon
  • Vance Thompson Vision
  • Omaha, Nebraska

Emily Schehlein

Emily M. Schehlein, MD
  • Cataract & Glaucoma Surgeon
  • Brighton Vision Center
  • Brighton, Michigan

Manjool Shah Headshot

Manjool Shah, MD
  • Associate Professor and Program Director of Glaucoma Fellowship
  • NYU Langone Health Department of Ophthalmology
  • Physician, NYU Langone Health and Bellevue Hospital
  • New York, New York

Inder Paul Singh

Inder Paul Singh, MD
  • President and Ophthalmologist
  • The Eye Centers of Racine and Kenosha
  • Racine and Kenosha, Wisconsin

Swarup Sai Swaminathan

Swarup Sai Swaminathan, MD

  • Associate Professor of Clinical Ophthalmology
  • Bascom Plamer Eye Institute
  • University of Miami
  • Miami, Florida
  • Associate Professor of Public Health Sciences
  • University of Miami
  • Coral Gables, Florida

Zarmeena Vendal

Zarmeena Vendal, MD

  • Cataract & Glaucoma Surgeon
  • Founder, Westlake Eye Specialists
  • Austin, Texas

Financial Relationship Disclosures  

It is the policy of The Fundingsland Group (TFG) that faculty and other individuals in a position to control content of this activity disclose all financial relationships with ACCME defined ineligible companies within the past 24 months. TFG has policies in place that have identified relevant relationships and mitigated any real or apparent conflicts of interest prior to this educational activity.

Lorraine M. Provencher, MD, Faculty Member, has the following relevant financial relationships: Consultant: Elios Vision and Thea. Consultant & Speaker: AbbVie, Alcon and Glaukos. Speaker: RxSight. Research: BVI, Bausch+Lomb, and Carl Zeiss Meditec. Stockholder (publicly traded company): New World Medical. Stockholder (publicly traded company), Speaker, & Research: MicroSurgical Technology. Stock Options: Radius.

Emily M. Schehlein, MD, Faculty Member, has the following relevant financial relationships: Consultant: AbbVie, Elios Vision, Glaukos, and MicroSurgical Technology. Consultant and Speaker: Alcon.

Manjool Shah, MD, Faculty Member, has the following relevant financial relationships: Consultant: AbbVie, Alcon, Bausch + Lomb, Corza, Glaukos, MST, New World Medical, Sight Sciences. Speaker: AbbVie, Alcon, Glaukos, MST.

Inder Paul Singh, MD, Faculty Member, has the following relevant financial relationships: Consultant: BVI. Consultant, Speaker and Research: AbbVie, Alcon, Bausch+Lomb, Glaukos, Lumibird, New World Medical, Rayner and Zeiss. Research: Sight Sciences.

Swarup Sai Swaminathan, MD, Faculty Member, has the following relevant financial relationships: Consultant: AbbVie. Board/Committee Member and Consultant: Lumata Health. Other (Financial Support received): Elios Vision – Relationship has ended.

Zarmeena Vendal, MD, Faculty Member, has the following relevant financial relationships: Board/Committee Member and Consultant: Vialase. Board/Committee Member, Consultant, Research: Sight Sciences. Consultant: AbbVie, Alcon, Bausch+Lomb, Glaukos, and Ocular Therapeutic. Consultant and Research: Biotissue, Johnson & Johnson, and Rx Sight.

Laura Straub, Staff, has the following relevant financial relationships: Consultant: LaunchLab Partners, Powers and Company, MJM and Holliday Communications. The following financial relationships as a consultant have ended: Avisi Technologies, Nova Eye, Rayner, RxSight, STAAR Surgical and Zeiss.

 

All other Fundingsland Group staff, planners, reviewers, and writers have no financial relationships with ineligible companies.

All identified relevant financial relationships have been mitigated and the educational content thoroughly evaluated for fair, balanced, and safe, effective patient care.

Progress